May 06, 2026 09:03 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres | Bangladesh MP warns of refugee crisis if BJP wins West Bengal polls | Diplomatic row: Bangladesh summons Indian envoy over Himanta Biswa Sarma remarks | Supreme Court grants Pawan Khera anticipatory bail in case over allegations against Himanta Biswa Sarma's wife | ‘Not necessary to humiliate me with arrest’: Pawan Khera to SC over remarks on Himanta Biswa Sarma’s wife | ‘Let’s not choose for people capable of choosing’: Supreme Court to Centre on teen pregnancy termination | I-PAC co-founder Vinesh Chandel gets bail after Bengal polls conclude | Exit Polls Give Bengal to BJP—But One Survey Begs to Differ | Big defence push: Rajnath Singh to hold high-stakes talks with Italy’s Defence Minister | “Voting without fear”: PM Modi hails record turnout in West Bengal polls
Pfizer
WIKIMEDIA COMMONS

Pfizer to only get half of COVID-19 vaccines out this year due to logistics: Reports

| @indiablooms | Dec 04, 2020, at 02:45 pm

Washington/Sputnik: US drug giant Pfizer expects to ship just about half of the COVID-19 vaccines it originally planned for this year because of supply-chain problems, although it still expects to roll out more than a billion doses in 2021, the Wall Street Journal reported.

Scaling up the raw material supply chain took longer than expected, a Pfizer spokesperson told the newspaper on Thursday.

The outcome of the clinical trial, the spokesperson added, was somewhat later than the initial projection.

New York-headquartered Pfizer and Germany-based partner BioNTech SE had hoped to roll out 100 million vaccines world-wide by the end of this year, a plan that has now been reduced to 50 million, the report said.

The United Kingdom on Wednesday granted emergency-use authorization for the vaccine, becoming the first Western country to start administering doses.

The two-shot Pfizer vaccine is also being reviewed by the US Food and Drug Administration, where a similar authorization could come later this month and a rollout before the end of the year. The US regulator also is considering a vaccine developed by Cambridge, Mass.-based Moderna Inc. that could begin shipping before Christmas.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.